Edition:
United States

Biotec Pharmacon ASA (BIOTEC.OL)

BIOTEC.OL on Oslo Stock Exchange

7.55NOK
17 Oct 2017
Change (% chg)

kr0.24 (+3.28%)
Prev Close
kr7.31
Open
kr7.31
Day's High
kr7.65
Day's Low
kr7.31
Volume
17,149
Avg. Vol
80,093
52-wk High
kr13.55
52-wk Low
kr5.10

Chart for

About

Biotec Pharmacon ASA is a Norway-based biopharmaceutical company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company focuses on new solutions within wound care, cancer therapies and other immune related disease areas. It has a... (more)

Overall

Beta: -0.50
Market Cap(Mil.): kr321.24
Shares Outstanding(Mil.): 43.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.57 16.82
EPS (TTM): -- -- --
ROI: -- 14.96 11.24
ROE: -- 16.23 15.07

BRIEF-Biotec Pharmacon subsidiary expands into bio-manufacturing market

* ARCTICZYMES NEW PRODUCT LAUNCH TO SERVE THE BIO-MANUFACTURING MARKET SEGMENT

Sep 29 2017

BRIEF-Biotec enters into supply agreement for M-Glucan to pet sector

* BIOTEC HAS ENTERED INTO A SUPPLY AGREEMENT FOR M-GLUCAN TO THE PET SECTOR

Sep 25 2017

BRIEF-Biotec Pharmacon appoints Christian Jørgensen new CEO

* SAID JØRGENSEN WILL COMMENCE IN HIS POSITION ON OCT 2 AND SVEIN LIEN WILL RESIGN FROM HIS POSITION AS OF THE SAME DATE

Sep 13 2017

BRIEF-Biotec's Woulgan application to be reconsidered by UK Drug Tariff

* ‍BIOTEC BETAGLUCANS HAS RECEIVED POSITIVE FEEDBACK FROM UK DRUG TARIFF APPEAL PANEL​

Sep 12 2017

BRIEF-Biotec prolongs supply agreement for delivery of M-Glucan

* INNSIDEINFORMASJON-BIOTEC HAS PROLONGED SUPPLY AGREEMENT FOR DELIVERY OF MGLUCAN-OB INNSIDEINFORMASJON

Aug 29 2017

BRIEF-Biotec Pharmacon enters into supply agreement for M-Gard in USA

* DELIVERIES WILL START IMMEDIATELY WHILE PARTIES WORK ON COMPLEMENTARY SUPPLY AGREEMENT

Aug 25 2017

BRIEF-Biotec appeals UK drug tariff rejection

* SUBSIDIARY BIOTEC BETAGLUCANS HAS FILED APPEAL FOR REJECTION OF UK DRUG TARIFF REIMBURSEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 19 2017

BRIEF-Biotec Pharmacon pantent granted in the US

* PATENT ON TECHNOLOGY PLATFORM SBG GRANTED BIOTEC PHARMACON IN US Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 04 2017

BRIEF-UK Drug Tariff rejects current Woulgan application

* Subsidiary Biotec Betaglucan has received negative feedback from uk drug tariff regarding application for reimbursement

May 02 2017

BRIEF-Biotec Pharmacon Q1 EBITDA loss widens to NOK 4.1 mln

* Q1 EBITDA LOSS NOK 4.1 MILLION VERSUS LOSS NOK 3.5 MILLION YEAR AGO

Apr 27 2017

Earnings vs. Estimates